JPRN-UMIN000027210已完成2 期
A phase II trial of TAS-102 in combination with cetuximab for patients with RAS wild-type metastatic colorectal cancer refractory to previous anti-EGFR antibodies(WJOG8916G) - A phase II trial of TAS-102 in combination with cetuximab for metastatic colorectal cancer patients(WJOG8916G)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Previous grade 3/4 hypersensitivity reaction to Cmab 2) Another malignancy with less than 5 disease-free years 3) Presence of active local or systemic infection under treatment 4) Positive for Hepatitis B surface antigen 5) Radiographic evidence of severe pulmonary fibrosis or interstitial pneumonia on Computed Tomography 6) Symptomatic brain and/or leptomeningeal metastases which needs treatment 7) Serious complications 8) Clinically significant mental or psychological disorder 9) Patients requiring continuous treatment with systemic steroids 10) Females who are pregnant, breastfeeding, or with a positive pregnancy test or males and females of reproductive potential unwilling to use adequate contraception 11) Patients whose participation in the trial was judged to be inappropriate by the attending doctor
研究者
相似试验
已完成
2 期
A phase II trial of TAS-102 in combination with cetuximab for patients with RAS wild-type metastatic colorectal cancer refractory to previous anti-EGFR antibodies, accompanying research(WJOG8916GTR)Metastatic RAS wild type colorectal cancer which has become refractory or there was intolerance to chemotherapies (fluoropyrimidine, irinotecan, oxaliplatin) and bevacizumab, and refractory to anti- epidermal growth factor receptor(EGFR) antibodiesJPRN-UMIN000027211West Japan Oncology Group55
已完成
1 期
A phase I/II trial of TAS-102 in combination with irinotecan in Japanese patients with advanced gastric cancer refractory to standard chemotherapiesadvanced gastric cancer refractory to standard chemotherapiesJPRN-UMIN000031346St. Marianna University School of Medicine11
已完成
2 期
Phase II study of TAS-102 in patients with advanced gastric cancer after progression on 1 or 2 prior systemic chemotherapyadvanced gastric cancerJPRN-UMIN000007421ational Cancer Center Hospital East28
已完成
1 期
Multicenter Phase 1b/2 Trial of TAS-102 with Bevacizumab in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.advanced colorectal cancerJPRN-UMIN000012883ational Cancer Center Exploratory Oncology Research &Clinical Trial Center25
已完成
2 期
A phase II study of TAS102 for advanced/recurrent esophageal cancer resistant/intolerable to 5-FU, Platinum compounds, and Taxanenresectable, advanced or recurrent esophageal cancerJPRN-UMIN000019268Kyoto University Hospital40